Zhitong Finance App News, Jingtai Holdings (02228.HK) announced that the Group has successfully developed and verified two innovative topical ingredients — small molecule Remanagen™ (XTP-118) and the polypeptide AquaKine™ (XTP-016) — with both anti-hair loss and hair growth, using its industry-leading AI molecular discovery platform. This combination formula of “Gemini” molecules has been proven through rigorous human experiments to significantly surpass existing similar products in terms of anti-hair loss effects, safety, and speed of action. Both molecules have successfully passed the US New Cosmetic Ingredient INCI (International Cosmetic Ingredient Name) registration, and their combined formulation product Groland has also obtained the US FDA (Food and Drug Administration) cosmetics registration, marking the official entry of Jingtai's AI platform into the consumer health sector with great potential. In the future, Jingtai will not only attack drug research and development for major diseases, but also create consumer-grade molecular products that improve the quality of people's daily lives.

Zhitongcaijing · 11/10/2025 10:57
Zhitong Finance App News, Jingtai Holdings (02228.HK) announced that the Group has successfully developed and verified two innovative topical ingredients — small molecule Remanagen™ (XTP-118) and the polypeptide AquaKine™ (XTP-016) — with both anti-hair loss and hair growth, using its industry-leading AI molecular discovery platform. This combination formula of “Gemini” molecules has been proven through rigorous human experiments to significantly surpass existing similar products in terms of anti-hair loss effects, safety, and speed of action. Both molecules have successfully passed the US New Cosmetic Ingredient INCI (International Cosmetic Ingredient Name) registration, and their combined formulation product Groland has also obtained the US FDA (Food and Drug Administration) cosmetics registration, marking the official entry of Jingtai's AI platform into the consumer health sector with great potential. In the future, Jingtai will not only attack drug research and development for major diseases, but also create consumer-grade molecular products that improve the quality of people's daily lives.